What insurance policy changes affect CPT 67225?

There are 8 tracked policy changes affecting CPT 67225, including updates from Aetna, Independence Blue Cross. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 67225?

Payers that have issued tracked updates for CPT 67225 include: Aetna, Independence Blue Cross.

How do I get notified when CPT 67225 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 67225. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for CPT 67225?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

67225 — A light-activated drug treatment added to another eye procedure to destroy abnormal blood vessels or tissue.: Insurance Policy Changes

67225 Insurance Policy Changes

CPT 67225, in plain terms, covers A light-activated drug treatment added to another eye procedure to destroy abnormal blood vessels or tissue. CPT 67225 is referenced in 8 tracked payer policy changes from Aetna and Independence Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 67225 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Medium impact

Verteporfin (Visudyne) Photodynamic Therapy (CPB 0594, reviewed 2026-04-24)

Aetna·Effective Apr 24, 2026

Aetna's updated CPB 0594 (effective April 24, 2026) clarifies coverage criteria for Verteporfin (Visudyne) photodynamic therapy for ocular indications. Coverage is limited to predominantly classic subfoveal choroidal neovascularization (CNV) from wet AMD, pathologic myopia, presumed ocular histoplasmosis, or chronic central serous chorioretinopathy with lesion spot size ≤6.4mm, plus choroidal hemangioma. Combination therapy with anti-angiogenic agents remains experimental. Billing teams must ensure claims for non-covered indications are denied and prior authorization processes reflect the narrow covered criteria.

67225 Insurance Policy Changes

Age-Related Macular Degeneration (CPB 0765, reviewed 2026-01-14)

Verteporfin (Visudyne) Photodynamic Therapy (CPB 0594, reviewed 2026-04-24)

MA07.003f, Photodynamic Therapy Using Verteporfin (Visudyne®)

MA07.003f, Photodynamic Therapy Using Verteporfin (Visudyne®)

MA07.003f, Photodynamic Therapy Using Verteporfin (Visudyne®)

07.13.05m, Photodynamic Therapy (PDT) Using Verteporfin (Visudyne®)

07.13.05m, Photodynamic Therapy (PDT) Using Verteporfin (Visudyne®)

Age-Related Macular Degeneration (CPB 0765, reviewed 2026-10-14)